Role of Doppler Endoscopic Probe in the Diagnosis of Subepithelial Gastrointestinal Lesions. (DopplerSEL)

August 1, 2023 updated by: Francisco Baldaque-Silva

RESEARCH PLAN I-TITLE Role of Doppler endoscopic probe in the diagnosis of subepithelial gastrointestinal lesions.

II-BACKGROUND Subepithelial lesions (SEL) are commonly encountered during routine endoscopies with an estimated prevalence of 3.5%. Most of the SELs are detected during upper gastrointestinal endoscopy. Subsequently, endoscopic ultrasound (EUS) is performed to better characterize the lesion and to rule out the presence of a vascular lesion before tissue sampling due to the high risk of severe bleeding with tissue acquisition in vascular injury. However, EUS can rarely establish a definitive diagnosis per se with limited accuracy.

In large lesions, it is possible to use cytology or histology needles via the EUS instrument to collect cells/tissue within the lesion. It can lead to accurate diagnosis and consistent management. However, EUS-guided tissue sampling can be technically challenging, with poor yield for small or mobile SELs. In addition, EUS is an expensive technique, high operator dependency and performed only in tertiary centers. It creates a time gap between endoscopic detection and the EUS examination and increases costs. That delay in diagnosis is a source of anxiety for the patient and for the caregivers.

Several methods were proposed to increase the diagnostic yield of tissue acquisition techniques, such as "bite-on-bite" biopsies which showed a limited diagnostic yield. Alternatively, the "unroofing" technique has also been advocated for histological diagnosis. In unroofing, a loop is used to remove the normal epithelium covering the subepithelial lesions and after epithelial removal, a biopsy forceps or loop is used to sample subepithelial lesions. Other techniques include endoscopic resection by snare or submucosal dissection. These enable a surgical specimen but are technically demanding and have been complicated by perforation and bleeding in most series.

There is a need for a method that enables rapid diagnosis in the same session as endoscopic detection of SEL regardless of their size. That method should ideally enable histological diagnosis with low risks of complications and should not require high technical expertise and should not be highly dependent on the operator. The ideal solution to address the diagnosis of gastrointestinal (GI) SEL would be one that would provide a tissue sampling after exclusion of a highly vascular lesion, in the same session as endoscopic detection.

Doppler endoscopic probe (DEP) is a Doppler endoscopic probe specially developed for the GI system, which enables blood flow detection during endoscopy.

DEP is CE and FDA approved and can be used through the working channel of the endoscope. Unlike standard EUS, which requires advanced endoscopic training, DEP is much easier to use. It allows the characterization of lesions as non-vascular, venous or arterial. Recent studies have demonstrated the safety and efficacy of DEP in vascular characterization in the gastrointestinal tract.

III PURPOSE

Primary objective:

  • Proof of concept evaluation of the role of DEP in the characterization of GI SEL as non-vascular or vascular (arterial or venous)
  • Relationship between findings on DEP versus findings on EUS (considered the gold standard) regarding SEL characterization as non-vascular or vascular (arterial or venous).

Secondary purposes:

  • Accuracy in removing the histological characterization of subepithelial GI lesions.
  • Complications in connection with tissue acquisition
  • Inter-observer agreement of DEP and EUS results. IV METHODS This is a pilot projective feasibility study that will be run by Karolinska University Hospital in Stockholm Patients with subepithelial GI lesions were referred for EUS evaluation. The study will include 30 patients.

A conventional gastroscopy will be performed. After identification of the lesion, DEP is performed. The DEP probe is lubricated and deployed through the working channel of the endoscope. The probe will contact the mucosa slightly, covering the SEL. Then evaluate the lesion in 2 different angels. The results will be characterized and recorded qualitatively: no flow / arterial flow / venous flow and in terms of intensity: soft, medium or high.

After DEP, evaluation EUS will be performed by another endoscopist who will be tied to the DEP results. EUS will be considered the gold standard.

After both assessments, the lesion is characterized as no vessel / arterial / venous and as soft / medium / high flow intensity.

EUS will be followed by removal of SEL in patients where EUS excludes the presence of high vessel disease. "Unroofing" will be performed using a conventional endoscopic loop, through the working channel of the endoscope. After the surface of the lesion is disturbed, a biopsy forceps will be used for tissue acquisition. Tissue will be stored in formalin and processed and evaluated by the pathologist.

Study Overview

Detailed Description

RESEARCH PLAN

I-TITLE Role of doppler endoscopic probe in the diagnosis of subepithelial gastrointestinal lesions.

II-BACKGROUND

Subepithelial lesions (SELs) are commonly encountered on routine endoscopies with estimated prevalence of 3.5% (PMID: 24238309). Most small SELs are asymptomatic and benign, but their pathological diagnosis may be challenging, and sometimes impossible with conventional technology.

Most of SELs are detected during upper gastrointestinal endoscopy. Afterwards, endoscopic ultrasound (EUS) is usually performed in order to better characterize the lesion and to exclude the presence of a vascular lesion. EUS enables evaluation of the size, structure and location of the lesion within the GI wall (submucosa/muscularis mucosa/ submucosa/muscularis propria), but can seldom stablish a definitive diagnosis per se. EUS provides valuable information regarding the layer of origin and can suggest a diagnosis, but it has been shown to have limited accuracy. (PMID: 12190103).

In lesions larger than 2cm, it is possible to use dedicated cytologi (FNA) or histology (FNB) needles thought the EUS instrument in order to collect cells/tissue from within the lesion. That may lead to proper diagnosis and consequent management. However, EUS-guided tissue sampling can be technically challenging, with poor yields for small or mobile SELs (20306384). Additionally, EUS is an expensive technique, highly operator dependent and usually only performed in tertiary centers. That creates a time gap between the endoscopic detection and the EUS investigation, and increases the costs. That delay in the diagnosis is a source of anxiety for the patient and for health care providers alike.

In cases with small or mobile SEL, in which a definitive diagnosis cannot be stablished with EUS plus FNA/FNB, surveillance is recommended. But the later, is associated with high costs and high burden for the health care system.

Several methods were advocated to increase the diagnostic yield of tissue acquisition techniques such as "bite- on-bite" forceps biopsy that showed a limited diagnostic yield (PMID: 12518134), with one prospective study showing a diagnostic yield of only 17% compared with 87% with endoscopic resection (PMID: 16813799). Alternatively, unroofing technique has also been advocated in this context. With unroofing a snare is used to remove the normal epithelium that is covering the subepithelial lesion, and after epithelial removal a biopsy forceps is used to sample the subepithelial lesion. Other techniques include endoscopic resection by snaring or submucosal dissection. These enable a surgical specimen but are technically demanding and have been complicated by perforation and bleeding in most series.

Although endoscopic resection may have the advantage of providing both a complete pathological diagnosis as well as treatment for the tumor in selected patients, it is questionable whether endoscopic resection of the entire lesion is needed for diagnostic purposes, because of the associated long procedure time and potentially serious complications, such as bleeding and perforation.

EUS is usually performed before biopsy sampling, snaring or endoscopic resection in order to exclude the presence of a highly vascular SEL, due to the high risk of severe bleeding in case of tissue acquisition in a vascular lesion.

There is a need for a method that would enable rapid diagnosis in the same session as endoscopic detection of SELs irrespective of their size. That method should ideally enable histological diagnosis with low risks of complications and should not demand high technical expertise and should not be highly operator dependent. The ideal solution to address the diagnosis of gastrointestinal (GI) SEL would be one that would provide a tissue sampling after exclusion of a highly vascular lesion, in the same session as the endoscopic diagnosis.

Doppler endoscopic probe (DEP) is a 2-mm diameter, single-use, Doppler endoscopic probe (Vascular Technology Inc, Nashua, NH) specifically developed for GI tract, that enables blood flow detection during endoscopy. As lesions are unlikely to bleed substantially without a major supply of blood flow, the applicability of endoscopic DEP resides in the ability to detect blood flow within submucosal blood vessels that feed a potentially bleeding lesion within the GI tract.

DEP is CE and FDA approved and may be used through the working channel of the endoscope. The DEP system is a 20-MHz, pulsed-wave Doppler ultrasound unit with 3 preset scanning depths: from the surface to 1.5, 4, and 7 mm. It has an audible Doppler output signal but does not have a visual monitor display. The unit is portable and battery-powered. Unlike standard EUS, which requires advanced endoscopic training, DEP is much more straightforward to use (15557966). The applicability of endoscopic Doppler US resides in the ability to detect blood flow within submucosal blood vessels that feed a potentially bleeding lesion within the GI tract. A positive DEP signal has been defined as a repetitive and similar visual spiking waveform (or audible signal) of at least 3 consecutive cycle duration (indicating pulsatile blood flow and minimizing the chance of a false-positive signal) (PMID: 10968843).

Recent studies had demonstrated the safety and efficacy of DEP in the vascular characterization of gastrointestinal peptic ulcers (26318834, 28167214).

III- AIMS

Primary aims:

  • Proof-of-concept evaluation of the role of DEP in the characterization of GI SEL as highly vascular or non-highly vascular.
  • Correlation between findings on DEP versus finding on EUS (considered the gold standard) in terms of SEL characterization as highly vascular or non-highly vascular.

Secondary aims:

  • Accuracy of unroofing in the histological characterization of subepitelial GI lesions.
  • Complications associated with tissue acquisition through unroofing technique such as bleeding or perforation
  • Inter-observer agreement of the DEP findings.

IV- METHODS

STUDY DESIGN

This is a pilot prospective feasibility study that will be run by Karolinska University Hospital in Stockholm

STUDY POPULATION Patients with subepithelial GI lesions referred for EUS evaluation. The study will include 20 patients.

Inclusion criteria

- Presence of subepithelial lesion on the GI tract.

Exclusion criteria

  • Anticoagulation therapy that cannot be discontinued
  • Liver cirrhosis with coagulopathy or varices
  • Malignancy

All patients will receive a detailed explanation regarding the procedure, its risks, benefits, and alternatives, and provided written informed consent before inclusion (Appendix 1).

Participants clinical, demographic, and procedural information will be obtained and recorded at enrollment (Appendix 2).

Patients under antiplatelet or anticoagulant drugs will be handled according to published guidelines.

OUTCOME PARAMETERS PRIMARY OUTCOME PARAMETERS DEP. The auditory sound from arterial flow corresponds to a sound like a blood pressure "swish-swish," whereas venous flow is a low-pitched venous hum. Intensity will be recorded as soft, medium, or loud.

Doppler on EUS will be evaluated as standard using the color-doppler and also wave flow assessment.

SECONDARY OUTCOME PARAMETERS Adverse events are defined as any complication in which DEP, EUS, unroofing or related procedures are a contributing factor and include bleeding and perforation.

Perforation is defined as a full thickness breach in the GI wall with or without symptoms.

Intraprocedural bleeding is considered significant and a complication when:

  • blood transfusion is needed
  • premature termination of endoscopic occurs

Delayed bleeding is defined as clinical evidence of bleeding manifested by melena or hematochezia from up to 14 days after the procedure that demanded presentation to the emergency department, hospital admission or medical intervention.

Adverse events are classified as:

  • acute (during procedure)
  • early (<48 h)
  • late (>48 h).

In terms of severity they are characterized as:

  • mild (unplanned medical assistance, hospital admission, hospitalization <3 days, hemoglobin drop <3 g, no transfusion)
  • moderate (4-10 days hospitalization, <4 units blood transfusion, repeat endoscopic intervention, radiological intervention)
  • severe (hospitalization >10 days, intensive care unit (ICU) admission, need for surgery, >4 units blood transfusion) or fatal (death attributable to procedure) [7, 8].

ENDOSCOPIC PROTOCOL

A conventional gastroscopy will be performed. After identification of the lesion, DEP will be performed. The DEP probe will be lubricated and deployed through the working channel of the endoscope. The probe will contact slightly the mucosa covering the SEL. Then will evaluate the lesion in 2 different angels (one at the top and one at the base of the lesion). First, the superficial Doppler depth setting (< 1.5 mm) will be used, followed by the middle setting (< 4 mm). Assessment will be recorded and endoscopist diagnosis (arterial flow/venous flow, soft/medium/loud intensity) will be registered. All DEP will be performed by the same endoscopist (MO). Findings will be characterized and registered qualitatively: no flow/arterial flow/venous flow and in terms of intensity: soft, medium, or loud.

After DEP, evaluation EUS will be performed by another endoscopists (FBS) that will be blinded to the DEP findings. EUS will be considered the gold standard.

After both assessments the lesion will be characterized as no vascular/low vascular/highly vascular flow.

EUS will be followed by unroofing of the SEL in patients in which EUS excluded the presence of a highly vascular lesion. Unroofing will be performed using a conventional endoscopic snare, through the working channel of the endoscope. After the surface of the lesion is unroofed, a biopsy forceps will be used for tissue acquisition. Tissue will be stored in formalin and processed and evaluated by pathologist.

All data will be registered. All procedures will be recorded in video and audio (DEP).

POST PROCEDURE PROTOCOL

Before Discharge After unroofing, patients will be closely monitored for 2-4 hours under continuous monitoring and then discharged if no complications detected.

After Discharge At week 8 after discharge, patients will have a hospital visit for assessment of complications and control endoscopy.

V-SIGNIFICANCE With this study it will be possible to evaluate the strategy of DEP and unroofing in the assessment of GI SEL. In case of positive results: good accuracy in the diagnosis/exclusion of vascular lesions with DEP and good histological yield with unroofing, this strategy may be further validated and might change the paradigm of management of GI SEL.

Study Type

Interventional

Enrollment (Estimated)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Stockholm, Sweden, 11346
        • Recruiting
        • Karolinska University Hospital & Karolinska Institute
        • Contact:
          • Karolinska University Hospital & K Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Presence of subepithelial lesion on the GI tract.

Exclusion Criteria:

  • Anticoagulation therapy that cannot be discontinued
  • Liver cirrhosis with coagulopathy or varices
  • Malignancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention
Doppler endoscopic probe in the diagnosis of subepithelial gastrointestinal lesions
Doppler investigation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
DEP accuracy
Time Frame: From enrollment to the end of study at 8 weeks
DEP. The auditory sound from arterial flow corresponds to a sound like a blood pressure "swish-swish," whereas venous flow is a low-pitched venous hum. Intensity will be recorded as soft, medium, or loud. Doppler on EUS will be evaluated as standard using the color-doppler and also wave flow assessment.
From enrollment to the end of study at 8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2023

Primary Completion (Estimated)

December 31, 2023

Study Completion (Estimated)

December 31, 2023

Study Registration Dates

First Submitted

August 1, 2023

First Submitted That Met QC Criteria

August 1, 2023

First Posted (Actual)

August 9, 2023

Study Record Updates

Last Update Posted (Actual)

August 9, 2023

Last Update Submitted That Met QC Criteria

August 1, 2023

Last Verified

August 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • KarolinskaUH 2019-05404
  • 2019-05404 (Other Identifier: Swedish Ethical Review Authority)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Subepithelial Tumors of the Upper Gastrointestinal Tract

Clinical Trials on Doppler investigation

3
Subscribe